CORONA REMEDIES
|
CORONA REMEDIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 30.27 | 24.43 | 14.80 | 13.89 |
| CEPS(Rs) | 36.46 | 30.51 | 19.42 | 17.17 |
| DPS(Rs) | 10.00 | 7.31 | 3.70 | 2.77 |
| Book NAV/Share(Rs) | 122.12 | 99.14 | 78.55 | 66.80 |
| Tax Rate(%) | 23.00 | 24.73 | 23.61 | 23.41 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 21.27 | 20.42 | 14.92 | 14.25 |
| EBIT Margin(%) | 17.93 | 17.80 | 12.82 | 12.82 |
| Pre Tax Margin(%) | 17.43 | 16.89 | 11.42 | 12.35 |
| PAT Margin (%) | 13.42 | 12.72 | 8.73 | 9.46 |
| Cash Profit Margin (%) | 16.17 | 15.88 | 11.45 | 11.69 |
| Performance Ratios | ||||
| ROA(%) | 15.99 | 15.79 | 11.77 | 12.82 |
| ROE(%) | 27.36 | 27.50 | 20.36 | 20.79 |
| ROCE(%) | 31.74 | 32.59 | 25.93 | 28.03 |
| Asset Turnover(x) | 1.19 | 1.24 | 1.35 | 1.36 |
| Sales/Fixed Asset(x) | 2.25 | 2.38 | 2.81 | 3.50 |
| Working Capital/Sales(x) | -107.26 | 11.84 | 15.78 | 5.83 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.44 | 0.42 | 0.36 | 0.29 |
| Receivable days | 34.91 | 33.89 | 32.89 | 35.35 |
| Inventory Days | 33.67 | 35.38 | 35.85 | 42.83 |
| Payable days | 203.24 | 198.93 | 167.89 | 163.28 |
| Valuation Parameters | ||||
| PER(x) | 51.41 | - | - | - |
| PCE(x) | 42.68 | - | - | - |
| Price/Book(x) | 12.74 | - | - | - |
| Yield(%) | 0.64 | - | - | - |
| EV/Net Sales(x) | 6.85 | 0.05 | 0.12 | -0.01 |
| EV/Core EBITDA(x) | 31.62 | 0.22 | 0.78 | -0.10 |
| EV/EBIT(x) | 38.87 | 0.26 | 0.94 | -0.11 |
| EV/CE(x) | 10.81 | 0.08 | 0.20 | -0.03 |
| M Cap / Sales | 6.78 | - | - | - |
| Growth Ratio | ||||
| Net Sales Growth(%) | 17.28 | 17.94 | 14.75 | - |
| Core EBITDA Growth(%) | 23.66 | 52.56 | 19.37 | - |
| EBIT Growth(%) | 18.29 | 57.34 | 15.43 | - |
| PAT Growth(%) | 23.88 | 65.11 | 6.56 | - |
| EPS Growth(%) | 23.88 | 65.11 | 6.56 | - |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.19 | 0.10 | 0.28 | 0.01 |
| Current Ratio(x) | 0.97 | 1.30 | 1.24 | 1.74 |
| Quick Ratio(x) | 0.70 | 0.91 | 0.88 | 1.23 |
| Interest Cover(x) | 35.49 | 19.73 | 9.21 | 26.98 |
| Total Debt/Mcap(x) | 0.02 | - | - | - |
Compare Financial Ratios of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹12,087.6 Cr | -1.7% | 13.7% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹452,982.0 Cr | 0.9% | 5.6% | 14.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,361.0 Cr | 1.2% | 3.7% | -1.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹164,737.0 Cr | 4.4% | 10.3% | 42.1% | Stock Analytics | |
| CIPLA | ₹115,655.0 Cr | -1.7% | 3.1% | -4.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,573.0 Cr | 0.2% | 5.7% | 6% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | -1.7% |
13.7% |
|
| SENSEX | -0.5% |
3% |
-8.5% |
You may also like the below Video Courses
